Intellectual Property India Publishes Patent Application for 'Lyophilized Sovateltide-Based Injectable Formulation And A Process For Preparation' Filed by Pharmazz, Inc.

MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202518056350 A) filed by Pharmazz, Inc., Willowbrook, U.S.A., on June 11, for 'lyophilized sovateltide-based injectable formulation and a process for preparation.'

Inventor(s) include Lavhale, Manish S.; and Gulati, Dr. Anil.

The application for the patent was published on Sept. 26, under issue no. 39/2025.

According to the abstract released by the Intellectual Property India: "A lyophilized Sovateltide-based injectable formulation, comprising sovateltide in the range from about 0.01 to about 0.02% w/w, trisodium citrate dihydrate is present in the range of from about 20 to about 80% w/w and mannitol is present in the range of from about 20 to about 80% w/w. A reconstituted liquid composition comprising sovateltide; trisodium citrate; mannitol and water or 0.9% aqueous sodium chloride solution and process for the preparation of a lyophilized pharmaceutical composition of sovateltide comprising: dissolving sovateltide, trisodium citrate dihydrate and mannitol in water for injection; filter the solution through 0.2 membrane filter; fill the individual vials up to the target fill volume; and lyophilization of the filled vials."

The patent application was internationally filed on Dec. 18, 2023, under International application No.PCT/IB2023/062892.

Disclaimer: Curated by HT Syndication.